Importantly, PLZF/RARA-associated APL is resistant to ATO and exhibits impaired sensitivity to ATRA, giving rise to a significantly poorer clinical outcome compared to patients with classical PML-RARA+ disease, which typically responds to both of these molecularly-targeted therapies [13], [14]. The gene discussed is ZBTB16; the disease is acute promyelocytic leukemia.